Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621280 · ClinicalTrials.gov registry record · Phase 3
Open-label Treatment in Cushing's Syndrome
A Phase 3 study of Cushing Syndrome and Cushing Disease, sponsored by Cortendo AB.
- Completed
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
- 20
- Study locations
NCT03621280 is a Phase 3 study of Cushing Syndrome and Cushing Disease that has completed, run by Cortendo AB. The registered enrollment target is 51 participants, below the 175-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT03621280, a Phase 3 study of Cushing Syndrome and Cushing Disease, has completed, sponsored by Cortendo AB.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.
Conditions Studied
Interventions
- DRUG Levoketoconazole
Study Locations (20)
Other
- Sveti Georgy University Hospital Clinic of Endocrinology and Metabolic Diseases - Plovdiv
- Alexandovska University Hospital - Sofia
- University Specialized Hospital for Active Treatment in Endocrinology - Sofia
- APHM Hôpital de la Conception - Marseille
- General Hospital of Athens Evangelismos Department of Endocrinology and Diabete - Athens
- Hippokration General Hospital Endocrinology and Diabetes Department - Thessaloniki
- Semmelweis Egyetem II. Belgyógyászati Klinika - Budapest
- Bnai Zion Medical Center Endocrinology Institute - Haifa
- Rabin Medical Center, Beilinson Campus - Petah Tikva
- Tel Aviv-Sourasky Medical Center Institute Endocrinology Metabolism & Hypertension - Tel Aviv
- Clinica Endocrinologia malattie del Metabolismo - Ancona
- AOU Policlinico G. Martino Sezione di Endocrinologia - Messina
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- The Center for Diabetes and Endocrine Care - Fort Lauderdale
Georgia
- Emory University - Atlanta
Missouri
- Washington University School of Medicine - St Louis
New Mexico
- University of New Mexico HSC - HSC Sponsored Projects Office - Albuquerque
Ohio
- Cleveland Clinic - Cleveland
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-01-07 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03621280
The ClinicalTrials.gov registry entry for NCT03621280 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (71% lower). The listed sponsor is Cortendo AB, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cushing Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Levoketoconazole is the first listed.
NCT03621280 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT03621280 about?
NCT03621280 is a clinical study titled "Open-label Treatment in Cushing's Syndrome". This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.
What is the current status of trial NCT03621280?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2019-01-07. Estimated completion is 2022-12-31.
What conditions does trial NCT03621280 study?
This clinical trial studies the following conditions: Cushing Syndrome, Cushing Disease.
What interventions are being tested in trial NCT03621280?
The interventions under investigation include: Levoketoconazole (DRUG).
Who is sponsoring clinical trial NCT03621280?
This trial is sponsored by Cortendo AB, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03621280 being conducted?
This trial has 20 study locations across Florida, Georgia, Missouri, New Mexico, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
COMPLETED · Phase 3
-
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
RECRUITING · Phase 1
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RECRUITING
-
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
RECRUITING
-
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.